fig1

Figure 1. Effect of leelamine (LLM) treatment on expression and activity of cMyc in human prostate cancer cells. The effect of LLM treatment on the protein level of cMyc in 22Rv1 and LNCaP cells as determined by western blotting. The blots were probed with an anti-GAPDH antibody to correct for differences in protein loading. The numbers above bands represent quantitation of the cMyc protein level change relative to corresponding ethanol-treated control (A). Confocal microscopic images of cMyc protein (green fluorescence) in vehicle-treated control and LLM-treated 22Rv1 and LNCaP cells. DRAQ5 (blue fluorescence) was used for nuclear staining (B). The effect of LLM treatment on mRNA level of cMyc. The results shown are mean ± SD (n = 3). *Significantly different (P < 0.05) compared with corresponding ethanol-treated control by one-way ANOVA followed by Dunnett’s test (C). The effect of LLM treatment on the activity of cMyc as determined by luciferase reporter assay. The results shown are mean ± SD (n = 3). *Significantly different (P < 0.05) compared with ethanol-treated control by one-way ANOVA followed by Dunnett’s test (D). Each experiment was performed twice, and the results were generally consistent.